ClinicalTrials.gg
Not yet recruitingNCT07908524TroFuse-01AUpdated Nov 2, 2026

MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)

A Phase 1/2 interventional study of Sacituzumab tirumotecan and Rescue medication in Metastatic Castration-resistant Prostate Cancer, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Updated Nov 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies testing prednisone in Prostatic Neoplasms — 9 open to participants now, 17 under way, 1 of them phase 3. Prednisone · Prostatic Neoplasms.

Planned enrollment
12th of 73
290 · median 57
Started
2026
with 2 others
Phase 1/2
11 of 75
2 open now
Primary completion
2032-06
later than 15 of 16 live
Registered
75th of 75
by date

Among the 75 studies testing prednisone in Prostatic Neoplasms, this one is the 12th largest by planned enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 1/2, reaches primary completion later than 15 of the 16 other live ones, and was the 75th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 75 studies testing prednisone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About prednisone

Prednisone: first FDA approval 1955 (METICORTEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing prednisone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer/androgen pathway modulator refractory (mCRPC/APMR). Current treatment for mCRPC includes chemotherapy, such as docetaxel. Chemotherapy is medicine that works to destroy cancer cells or stop them from growing.

In this trial, researchers want to learn if giving sacituzumab tirumotecan (sac-TMT) alone or with other treatments can treat mCRPC. Sac-TMT is a trial medicine that is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. Opevesostat is another trial medicine designed to block the body from making steroid hormones that cause the cancer cells to grow.

The goals of this trial are to learn:

  • How many participants have the cancer respond (gets smaller or goes away) to the trial treatments
  • About the safety of the trial treatments and if participants tolerate the treatments. Tolerate means participants will receive the trial treatments unless they need to stop it due to health problems.
Read the detailed description

This is a substudy of the master protocol MK-2870-U01.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Have or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
  • Have prostate cancer progression while on androgen deprivation therapy (ADT) or post-bilateral orchiectomy
  • Have received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) (eg, abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for non- hormone-sensitive prostate cancer (nmHSPC)/androgen pathway modulation sensitive (APMS), metastatic hormone-sensitive prostate cancer (mHSPC)/APMS, non-metastatic castration-resistant prostate cancer (nmCRPC)/ androgen pathway modulation (APMR), or metastatic castration-resistant prostate cancer (mCRPC)/APMR and progressed during or after at least 8 weeks of treatment (≥14 weeks of treatment for participants with bone progression)
  • Have had prior treatment with poly adenosine diphosphate ribose polymerase inhibitor (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
  • Participants with microsatellite instability (MSI)-high/deficient mismatch repair (dMMR) must have received programmed cell death 1 protein () blocking antibody-based immunotherapy when indicated by local approved regimen, or be considered ineligible for PD-1-blocking antibody-based immunotherapy by the investigator

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Is unable to swallow tablets/capsules
  • Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has received prior treatment with taxane-based chemotherapy agent for mCRPC/APMR
  • Has received prior therapy with trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) or topoisomerase I inhibitor (TOP1i) payload ADC
  • Has had a "superscan" bone scan
  • Known additional that is progressing or has required active treatment within the past 3 years
  • Known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required , has current pneumonitis/interstitial lung disease, or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
290 participants (estimated)

Study arms

  • Active comparator
    Docetaxel

    Participants will receive docetaxel every 3 weeks by intravenous (IV) infusion. Participants will also receive either prednisone or prednisolone daily (or per approved product label).

    Drug: Docetaxel · Drug: Prednisone · Drug: Prednisolone

  • Experimental
    Sac-TMT (Dose 1)

    Participants will receive sac-TMT monotherapy every 2 weeks (q2w) by IV infusion.

    Biological: Sacituzumab tirumotecan · Drug: Rescue medication

  • Experimental
    Sac-TMT (Dose 2)

    Participants will receive sac-TMT monotherapy q2w by IV infusion.

    Biological: Sacituzumab tirumotecan · Drug: Rescue medication

  • Experimental
    Sac-TMT Plus Opevesostat

    Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of opevesostat twice daily until any of the criterion for discontinuation are met. Participants receiving opevesostat will receive fludrocortisone and dexamethasone daily.

    Biological: Sacituzumab tirumotecan · Drug: Rescue medication · Drug: Opevesostat · Drug: Fludrocortisone · Drug: Dexamethasone

  • Experimental
    Sac-TMT Plus Androgen Receptor Pathway Inhibitor (ARPI): Abiraterone Acetate or Enzalutamide

    Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of an androgen receptor pathway inhibitor (ARPI), either abiraterone acetate daily or enzalutamide daily until any of the criterion for discontinuation are met. Participants receiving abiraterone acetate will also receive either prednisone or prednisolone daily (or per approved product label).

    Biological: Sacituzumab tirumotecan · Drug: Rescue medication · Drug: Prednisone · Drug: Abiraterone acetate · Drug: Enzalutamide · Drug: Prednisolone

Interventions

  • IV infusion

    Also known as: sac-TMT, MK-2870, SKB264

  • DrugRescue medication

    Participants receiving sac-TMT may be administered the following rescue medications according to the approved product: granulocyte colony-stimulating factor, histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and steroid mouthwash (dexamethasone or equivalent).

  • IV infusion

  • Oral administration

  • Oral administration

    Also known as: MK-5684

  • Oral administration

  • Oral administration

  • Oral administration

  • Oral administration

  • Oral administration

06

What researchers measure

Primary outcomes

  1. Efficacy Phase: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Prostate Cancer Working Group 4 (PCWG4)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 66 months

  2. Efficacy Phase: Number of Participants Who Experience at Least One Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience at least one AE will be reported.

    Time frame: Up to approximately 66 months

  3. Efficacy Phase: Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 66 months

  4. Safety Lead-In (Combination Arms Only): Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)

    DLT will be defined as any drug-related AE observed during the DLT evaluation period (up to 28 days after the first dose of study intervention or prior to the third dose, whichever occurs first) that results in a change to a given dose or a delay in initiating the next treatment. The number of participants who experience a DLT will be reported.

    Time frame: Up to approximately 28 days

  5. Safety Lead-In (Combination Arms Only): Number of Participants Who Experience at Least One AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience at least one AE will be reported.

    Time frame: Up to approximately 66 months

  6. Safety Lead-In (Combination Arms Only): Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention will be reported.

    Time frame: Up to approximately 66 months

Secondary outcomes

  1. Efficacy Phase: Prostate-Specific Antigen (PSA) Response Rate

    PSA response is defined as having a postbaseline PSA reduction of at least 50% from baseline with a consecutive confirmation assessment at least 3 weeks later. The percentage of participants with a PSA response will be reported.

    Time frame: Up to approximately 66 months

  2. Efficacy Phase: Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time from randomization/allocation (Safety Lead-in) to the first documented progressive disease (PD), as assessed by PCWG4-Modified RECIST 1.1, or death from any cause, whichever occurs first. PD is defined as an increase of at least 20% in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. rPFS as assessed by BICR will be presented.

    Time frame: Up to approximately 66 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2032, 66 months later.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 66 months is above that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Nov 2, 2026
StartEst.
Dec 14, 2026
Primary completionEst.
Jun 29, 2032
CompletionEst.
Jun 29, 2032
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07908524
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
Dec 14, 2026 (estimated)
Primary completion
Jun 29, 2032 (estimated)
Completion
Jun 29, 2032 (estimated)
Last update
Nov 2, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacituzumab tirumotecan · Prednisone · Prednisolone

Start the discussion